SPH Notices - Multiple

1
Disclosure of beginning to have substantial holding
Section 276, Financial Markets Conduct Act 2013
To NZX Limited
and
To Promisia Healthcare Limited
Date this disclosure made: 6 August 2024
Date on which substantial holding began: 5 August 2024
Substantial product holder(s) giving disclosure
Full name(s): Algidus Investments Limited
Summary of substantial holding
Class of quoted voting products: Quoted equity warrants in Promisia Healthcare Limited
(NZX: PHLWA)
Summary for Algidus Investments Limited
For this disclosure,—
(a) total number held in class: 250,000,000
(b) total in class: 4,000,000,000
(c) total percentage held in class: 6.25%
Details of relevant interests
Details for Algidus Investments Limited
Nature of relevant interest(s): Registered holder of financial products
For that relevant interest,—
(a) number held in class: 250,000,000
(b) percentage held in class: 6.25%
(c) current registered holder(s): Algidus Investments Limited
(d) registered holder(s) once transfers are registered: Algidus Investments Limited
For a derivative relevant interest, also—
(a) type of derivative: N/A
(b) details of derivative: N/A
(c) parties to the derivative: N/A

2
(d) if the substantial product holder is not a party to the derivative, the nature of the
relevant interest in the derivative: N/A
Details of transactions and events giving rise to substantial holding
Details of the transactions or other events requiring disclosure: 1 warrant issued for every
share subscribed for under Promisia’s capital raise offer announced to market on 2 July
2024.
Additional information
Address(es) of substantial product holder(s): Algidus Investments Limited c/- Duncan
Cotterill, Level 5, 50 Customhouse Quay, Wellington 6011
Contact details: Matt Yates, +64 4 471 9428 / matt.yates@duncancotterill.com

Certification
I, Matt Yates, certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make this disclosure
by all persons for whom it is made.

---

1
Disclosure of beginning to have substantial holding
Section 276, Financial Markets Conduct Act 2013
To NZX Limited
and
To Promisia Healthcare Limited
Date this disclosure made: 6 August 2024
Date on which substantial holding began: 5 August 2024
Substantial product holder(s) giving disclosure
Full name(s): Asset Management Limited
Summary of substantial holding
Class of quoted voting products: Quoted equity warrants in Promisia Healthcare Limited
(NZX: PHLWA)
Summary for Asset Management Limited
For this disclosure,—
(a) total number held in class: 1,775,000,000
(b) total in class: 4,000,000,000
(c) total percentage held in class: 44.375%
Details of relevant interests
Details for Asset Management Limited
Nature of relevant interest(s): Registered holder of financial products
For that relevant interest,—
(a) number held in class: 1,775,000,000
(b) percentage held in class: 44.375%
(c) current registered holder(s): Asset Management Limited
(d) registered holder(s) once transfers are registered: Asset Management Limited
For a derivative relevant interest, also—
(a) type of derivative: N/A
(b) details of derivative: N/A
(c) parties to the derivative: N/A

2
(d) if the substantial product holder is not a party to the derivative, the nature of the
relevant interest in the derivative: N/A
Details of transactions and events giving rise to substantial holding
Details of the transactions or other events requiring disclosure: 1 warrant issued for every
share subscribed for under Promisia’s capital raise offer announced to market on 2 July
2024.
Additional information
Address(es) of substantial product holder(s): Asset Management Limited c/- Duncan
Cotterill, Level 5, 50 Customhouse Quay, Wellington 6011
Contact details: Matt Yates, +64 4 471 9428 / matt.yates@duncancotterill.com

Certification
I, Matt Yates, certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make this disclosure
by all persons for whom it is made.

---

1
Disclosure of beginning to have substantial holding
Section 276, Financial Markets Conduct Act 2013
To NZX Limited
and
To Promisia Healthcare Limited
Date this disclosure made: 6 August 2024
Date on which substantial holding began: 5 August 2024
Substantial product holder(s) giving disclosure
Full name(s): Withlaro Holdings Limited
Summary of substantial holding
Class of quoted voting products: Quoted equity warrants in Promisia Healthcare Limited
(NZX: PHLWA)
Summary for Withlaro Holdings Limited
For this disclosure,—
(a) total number held in class: 250,000,000
(b) total in class: 4,000,000,000
(c) total percentage held in class: 6.25%
Details of relevant interests
Details for Withlaro Holdings Limited
Nature of relevant interest(s): Registered holder of financial products
For that relevant interest,—
(a) number held in class: 250,000,000
(b) percentage held in class: 6.25%
(c) current registered holder(s): Withlaro Holdings Limited
(d) registered holder(s) once transfers are registered: Withlaro Holdings Limited
For a derivative relevant interest, also—
(a) type of derivative: N/A
(b) details of derivative: N/A
(c) parties to the derivative: N/A

2
(d) if the substantial product holder is not a party to the derivative, the nature of the
relevant interest in the derivative: N/A
Details of transactions and events giving rise to substantial holding
Details of the transactions or other events requiring disclosure: 1 warrant issued for every
share subscribed for under Promisia’s capital raise offer announced to market on 2 July
2024.
Additional information
Address(es) of substantial product holder(s): Withlaro Holdings Limited c/- Duncan
Cotterill, Level 5, 50 Customhouse Quay, Wellington 6011
Contact details: Matt Yates, +64 4 471 9428 / matt.yates@duncancotterill.com

Certification
I, Matt Yates, certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make this disclosure
by all persons for whom it is made.

---

1
Disclosure of beginning to have substantial holding
Section 276, Financial Markets Conduct Act 2013
To NZX Limited
and
To Promisia Healthcare Limited
Date this disclosure made: 6 August 2024
Date on which substantial holding began: 5 August 2024
Substantial product holder(s) giving disclosure
Full name(s): Craig Barry Percy
Summary of substantial holding
Class of quoted voting products: Quoted equity warrants in Promisia Healthcare Limited
(NZX: PHLWA)
Summary for Craig Barry Percy
For this disclosure,—
(a) total number held in class: 200,000,000
(b) total in class: 4,000,000,000
(c) total percentage held in class: 5%
Details of relevant interests
Details for Craig Barry Percy
Nature of relevant interest(s): Registered holder of financial products
For that relevant interest,—
(a) number held in class: 200,000,000
(b) percentage held in class: 5%
(c) current registered holder(s): Craig Barry Percy
(d) registered holder(s) once transfers are registered: Craig Barry Percy
For a derivative relevant interest, also—
(a) type of derivative: N/A
(b) details of derivative: N/A
(c) parties to the derivative: N/A

2
(d) if the substantial product holder is not a party to the derivative, the nature of the
relevant interest in the derivative: N/A
Details of transactions and events giving rise to substantial holding
Details of the transactions or other events requiring disclosure: 1 warrant issued for every
share subscribed for under Promisia’s capital raise offer announced to market on 2 July
2024.
Additional information
Address(es) of substantial product holder(s): 6 Pembroke Crescent, Glendowie, Auckland,
1071, New Zealand
Contact details: Matt Yates, +64 4 471 9428 / matt.yates@duncancotterill.com

Disclosure has effect for purposes of directors’ and senior managers’ disclosure
Craig Barry Percy is also a director of Promisia Healthcare Limited. This disclosure also
constitutes disclosure for the purposes of the directors’ and senior managers’ disclosure
obligations.
Certification
I, Matt Yates, certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make this disclosure
by all persons for whom it is made.